1. |
Becker KF, Rosivatz E, Blechschmidt K, et al. Analysis of the Ecadherin repressor Snail in primary human cancers [J]. Cells Tissues Organs, 2007, 185(1): 204212.
|
2. |
Kokudo T, Suzuki Y, Yoshimatsu Y, et al. Snail is required for TGFβ induced endothelialmesenchymal transition of embryonic stem cellderived endothelial cells [J]. J Cell Sci, 2008, 121(Pt20): 33173324.
|
3. |
Mathias RA, Simpson RJ. Towards understanding epithelialmesenchymal transition: a proteomics perspective [J]. Biochim Biophys Acta, 2009, 1794(9): 13251331.
|
4. |
Voulgari A, Pintzas A. Epithelialmesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic [J]. Biochim Biophys Acta, 2009, 1796(2): 7590.
|
5. |
尋風華, 熊正文. 轉錄因子Snail與女性常見腫瘤關系研究進展 [J]. 中國婦幼保健雜志, 2011, 25(1): 6972.
|
6. |
Dai J, Rabie AB. VEGF: an essential mediator of both angiogenesis and endochondral ossifycation [J]. J Dent Res, 2007, 86(10): 937950.
|
7. |
程紅, 戴林, 郭雙評, 等譯. 乳腺及女性生殖器官腫瘤病理學和遺傳學 [M]. 北京: 人民衛生出版社, 2006: 13.
|
8. |
Sugimachi K, Tanaka S, Kameyama T, et al. Transcriptional repressor snail and progression of human hepatocellular carcinoma [J]. Clin Cancer Res, 2003, 9(7): 26572664.
|
9. |
李偉, 熊正文, 李宏偉, 等. COX2、VEGF、Ecad在乳腺癌組織中的表達及臨床病理意義 [J].中國現代普通外科進展, 2010, 13(10): 766771.
|
10. |
Olmeda D, Montes A, MorenoBueno G, et al. Snai1 and snai2 collaborate on tumor growth and metastasis propertiesof mouse skin carcinoma cell lines [J]. Oncogene, 2008, 27(34): 46904701.
|
11. |
Lee MY, Chou CY, Tang MJ, et al. Epithelialmesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail upregulation [J]. Clin Cancer Res, 2008, 14(15): 47434750.
|
12. |
Gholam D, Chebib A, Hauteville D, et al. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor positive, estrogen receptor negative, progesterone receptor negative and human epidermal growth factor receptor breast cancer [J]. Anticancer Drugs, 2007, 18(7): 835837.
|
13. |
Dunnwald LK, Rossing MA, Li Ci. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients [J]. Breast Cancer Res, 2007, 9(1): R6.
|
14. |
Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer [J]. Tumori, 2008, 94(3): 370383.
|
15. |
王宏波, 紀常生, 張軍. p53和cerbB2與胃癌關系的研究進展 [J]. 中國普外基礎與臨床雜志, 2010, 17(8): 880884.
|
16. |
蘇瓊, 舒寬勇, 伍瓊芳. PTEN、BCL2 和 CerbB2 蛋白在子宮內膜癌的表達及臨床意義 [J]. 江西醫藥, 2011, 46(2): 114117.
|
17. |
劉萍, 田薇薇, 梁冰. 非小細胞肺癌組織中CerbB2蛋白的表達 [J]. 鄭州大學學報(醫學版), 2006, 41(5): 917918.
|
18. |
熊正文, 范水平, 馮驥良, 等. CD44與V EGF 在顱內轉移瘤與膠質母細胞瘤中的表達研究 [J]. 實用醫技雜志, 2005, 12(11): 32123215.
|
19. |
李偉, 熊正文, 李宏偉. COX2、VEGF、Ecad在乳腺癌中的研究進展 [J]. 醫學綜述, 2010, 16(19): 29362940.
|
20. |
Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for nonsmall cell lung cancer [J] . Lung, 2005, 183(1): 2942.
|
21. |
胡帥爾, 張雅潔, 崔玉梅, 等. VEGFA和VEGFC在乳腺癌組織中的表達及其意義 [J] . 癌癥, 2005, 24(9): 10761079.
|
22. |
Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the antiproliferative activity of antihormones [J]. Endocr Relat Cancer, 2006, 13(3): 905919.
|
23. |
彭鵬, 鄒文蓉. p53, VEGF, Bcl2在進展期胃癌組織中的表達 [J]. 現代醫藥衛生, 2011, 27(2): 184185.
|
24. |
付能高, 陳小芬. VEGF和CD34在骨肉瘤組織中的表達及臨床意義 [J]. 現代醫藥衛生, 2010, 26 (9): 12811282.
|
25. |
張杰, 許俊龍, 張學東, 等. 甲狀腺乳頭狀癌VEGF、MMP9及COX2蛋白表達與淋巴道轉移和血管生成的相關性 [J]. 腫瘤防治研究, 2010, 37(4): 441444.
|